Proje Başlığı (TR) / 223S5094: Osteoartritin Tanısı, Seyri ve Tedavisinin İzlenmesi Amacıyla Fosfopeptit Zenginleştimesine Yönelik yeni bir İmmobilize Metal Afinite Kromatografisi (IMAC) Sorbentinin Geliştirilmesi ve bu Sorbentin Hastalıklı Eklem Sıvısının Proteomik, Metabolomik ve Lipidomik Araştırmalarında Kullanılarak Omik Haritalandırmanın Gerçekleştirilmesi
Project Title (ENG) / 223S5094: Development of a new Immobilized Metal Affinity Chromatography (IMAC) Sorbent for Phosphopeptide Enrichment for Monitoring the Diagnosis, Course, and Treatment of Osteoarthritis and Implementing the Omic Mapping of Synovial Fluid in Proteomic, Metabolomic and Lipidomic Studies
In 2012, the Foundation for the National Institutes of Health (FNIH) and the Osteoarthritis Research Society International (OARSI) developed a consortium with two major goals. The first is to standardize the scientific steps of biomarker research related to the development of treatments for OA and to identify factors in age, gender, physical activity and episodic changes of the disease that may affect baseline measurements. The second goal was to identify highly validated biomarkers that are predictive of clinical outcomes of OA. In line with the decisions of the consortium, a series of studies evaluating the role of specific biomarkers in the pathogenesis of OA and the metabolic impact of clinical treatments have been concluded. Drawing on the work of FNIH and OARSI, the biomarker validation process requires the precise identification of biomarkers based on sensitivity, specificity, false positive probability, and false negative probability. This issue was also brought to the agenda at the World OA Congress held between 17-20 March 2023 and it was decided to continue the work on this issue meticulously.
Early diagnosis of OA may lead to preventive measures of the disease and/or condition. The ultimate aim is to modify the natural course of the condition and slow down its development. Planning the treatment with the most appropriate approach and monitoring its success is equally important. Current OA diagnostics heavily relies on patient history, physical examination and radiology. These methodologies have limitations as the progression of the disease and/or the success of the treatment cannot be adequately monitored with such methods. Radiological findings and symptoms during physical examination may not always overlap with each other. These examination methods are also limited in the early diagnosis of OA. With magnetic resonance, articular cartilage can be imaged and mapped in certain centers with specific softwares. This approach, which requires trained medical staff and a developed infrastructure, is also expensive and may vary from assessment to assessment. The fact that OA does not cause homogeneous destruction on the joint surface additionally limits magnetic resonance methods.
There is a need to develop a reliable and economical biomarker-based approach that can provide rapid results at the bedside of the patient in order to diagnose OA as early as possible. Monitoring the success of treatments also seems to be essential. This issue was also addressed within the scope of the European Union’s OActive project (https://www.oactive.eu/) in 2018 and was supported with a budget of nearly five million Euros.
The Scientific and Technological Research Council of Türkiye (TÜBİTAK) granted the “Development of a new Immobilized Metal Affinity Chromatography (IMAC) Sorbent for Phosphopeptide Enrichment for Monitoring the Diagnosis, Course, and Treatment of Osteoarthritis and Implementing the Omic Mapping of Synovial Fluid in Proteomic, Metabolomic and Lipidomic Studies” project in relevance to the EU COST CA21110 – “Building an open European Network on OsteoArthritis research (NetwOArk)” Action.